Oxacillin
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Oxacillin: From Staphylococcal Infections to Epiglottitis
One-Sentence Summary
Oxacillin is a narrow-spectrum, penicillinase-resistant penicillin used to treat infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). The TxGNN model’s top-ranked prediction points to a possible link with Epiglottitis, but this is currently supported only by 0 clinical trials and 3 case-report-level publications, indicating a mechanism-based, very preliminary signal rather than established evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Staphylococcal (MSSA) infections — narrow-spectrum, penicillinase-resistant penicillin (no formal approved-indication text on file; drug currently not marketed in Taiwan) |
| Predicted New Indication | Epiglottitis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal DrugBank mechanism-of-action documentation is not yet available for this candidate (flagged as a High-severity data gap, DG002). Based on pharmacological information captured in the evidence pack, oxacillin is an antistaphylococcal penicillin that inhibits penicillin-binding proteins (PBPs), blocking bacterial cell wall synthesis and producing a bactericidal effect against MSSA.
Epiglottitis is classically caused by Haemophilus influenzae, streptococci, and only occasionally by staphylococci. Oxacillin’s mechanism is therefore only relevant in the subset of epiglottitis cases where a staphylococcal pathogen is confirmed — it is not a standard first-line treatment for epiglottitis in general, and the underlying literature reflects sporadic case reports rather than pathogen-directed treatment studies.
Notably, the same evidence pack contains a stronger, more clinically grounded signal further down the ranking: for bacterial arthritis (rank 3), oxacillin’s role is described as “one of its historically core uses” for MSSA septic arthritis rather than a novel repurposing candidate, and it carries better evidence (L3, decision stage S2, “Research Question”). This is discussed further in the closing section.
Clinical Trial Evidence
Currently no related clinical trials registered for epiglottitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3380744 | 1988 | Case Report | Pediatric Emergency Care | Unusual epiglottitis case in a child with asthma; failed to respond to aggressive asthma therapy, intubation revealed acute epiglottitis requiring appropriate antibiotic management |
| 4999568 | 1971 | Case Series/Review | British Medical Journal | Review of epiglottitis presentation and management in adults |
| 990756 | 1976 | Case Report | British Medical Journal | Acute epiglottiditis in an adult requiring tracheostomy |
Taiwan Market Information
Oxacillin is currently not marketed in Taiwan (0 licenses on file). No NDA/registration records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. (TFDA label warnings/contraindications are pending retrieval — flagged as a Blocking data gap, DG001, required before any S1 safety screening can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (epiglottitis) is supported only by mechanistic plausibility and three case-report-level publications, with no clinical trials and no confirmation that staphylococcal pathogens drive typical epiglottitis presentations. Combined with the drug’s non-marketed status in Taiwan and missing safety label data, evidence is insufficient to advance.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Blocking gap DG001) before any safety screening
- Formal DrugBank MOA confirmation (High-priority gap DG002)
- Pathogen-confirmed (staphylococcal) case series or comparative studies specific to epiglottitis
- Regulatory feasibility assessment given oxacillin’s current non-marketed status in Taiwan
Note on alternative candidate: Among the four indications predicted for this drug, bacterial arthritis (rank 3, L3, decision stage S2, “Research Question”) is substantially better supported — it reflects oxacillin’s established historical role in treating MSSA septic arthritis, with two relevant Phase 4 trials (NCT04141787, NCT04563325) and directly related cohort literature (e.g., PMID 25672426 on oxacillin-sensitive vs. -resistant S. aureus joint infections). This may warrant separate follow-up as a “confirm existing use” track rather than a novel repurposing hypothesis. The other two candidates (laryngitis, urinary tract infection) show weak, largely indirect evidence and are also recommended for Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.